PRNewsWire
18 Nov 2025, 16:00 UTC · 44w ago
Verdict
Headline leans bearish. We score TLX −1.00 across four claims.
Score confirms the headline.
Leans bearish
From its wording — no explicit rating
−1.00strongly bearish
What the story claims
4 claims · scored −1 bearish … +1 bullish
Telix received a FDA Complete Response Letter for its Zircaix BLA, citing deficiencies in chemistry, manufacturing, and controls, and requiring additional data to establish comparability between the phase 3 trial drug product and the commercial manufacturing process.
More negative than 99% of claims this week
The FDA issued notices of deficiency to Telix's third-party manufacturing and supply chain partners that must be remediated prior to resubmitting the Zircaix BLA.
Continue reading
5 related stories
More negative than 95% of ticker scores this week
Scored by the NIS engine · methodology.
Search tags
More negative than 99% of claims this week
Telix revealed it is the subject of an SEC investigation into its disclosures regarding the development of its prostate cancer therapeutic candidates TLX591 and TLX592.
More negative than 98% of claims this week
A securities class action lawsuit alleges Telix materially overstated the progress of its prostate cancer candidates and the quality of its supply chain and manufacturing partners.
More negative than 91% of claims this week
Which stocks this story touches
More negative than 95% of ticker scores this week
The company is facing a securities class action lawsuit following an SEC subpoena and an FDA rejection letter.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
8h ago
+21.8%
Price is moving against the score
$11.16 vs $9.16 close before publication (Nov 17) · not market-adjusted
TLX chart →
